The role of exosomal PD-L1 in NSCLC immunotherapy
Zhu Li1, Shichang Zhang1, Yue Wang1
1Pharmacology and Toxicology, Wright State University, Fairborn, OH, USA.
Abstract:
Therapeutic resistance and immune evasion are hallmark features associated with tumor progression, wherein tumor cells utilize programmed death-ligand 1 (PD-L1) to inhibit cytotoxic T-cell activity via programmed cell death protein 1 (PD-1) engagement. Anti-PD-1 monoclonal antibodies have shown tremendous success in multiple cancers. Despite their limited efficacy in non-small cell lung cancer (NSCLC), a deeper investigation into the mechanism of PD-L1-mediated immune evasion is needed to combat therapeutic resistance. While some clinical benefits for anti-PD-L1 therapy have been observed in NSCLC, factors, such as durability of response and resistance mechanisms remain barriers to its broader use. Recent findings suggest that exosomal PD-L1 may serve as a critical mediator in these resistance mechanisms while simultaneously promoting cancer progression. Therapeutically targeting the process of exosome biogenesis, which is controlled by neutral sphingomyelinase 2 (nSMase2) and the Rab proteins, could yield a novel treatment strategy. Evidence suggests that knocking down these regulatory proteins may enhance cancer therapy, but that remains to be seen in NSCLC. This review presents a comprehensive overview of exosomal PD-L1 in lung cancer, considering its implications in therapeutic resistance and novel treatment strategies, positioning it as a valuable resource for advancing next-generation immunotherapy approaches.
Insights
Exosomal programmed death-ligand 1 (PD-L1) promotes non-small cell lung cancer (NSCLC) progression and therapeutic resistance. Targeting exosome biogenesis offers a novel strategy to overcome immunotherapy resistance in NSCLC.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Tumor cells use programmed death-ligand 1 (PD-L1) to evade cytotoxic T-cell responses via programmed cell death protein 1 (PD-1) engagement.
- Anti-PD-1/PD-L1 immunotherapies show success in various cancers but face limitations in non-small cell lung cancer (NSCLC).
- Mechanisms of therapeutic resistance and immune evasion in NSCLC warrant further investigation.
Purpose of the Study:
- To review the role of exosomal PD-L1 in NSCLC therapeutic resistance.
- To explore novel treatment strategies targeting exosome biogenesis for overcoming immunotherapy resistance.
- To provide a comprehensive overview of exosomal PD-L1 in lung cancer for advancing immunotherapy.
Main Methods:
- Literature review of studies on PD-L1, exosomes, and immunotherapy in NSCLC.
- Analysis of mechanisms of exosome biogenesis regulated by neutral sphingomyelinase 2 (nSMase2) and Rab proteins.
- Synthesis of current evidence on exosomal PD-L1's role in therapeutic resistance.
Main Results:
- Exosomal PD-L1 is implicated as a mediator of therapeutic resistance and cancer progression in NSCLC.
- Targeting exosome biogenesis pathways, involving nSMase2 and Rab proteins, presents a potential therapeutic strategy.
- Understanding exosomal PD-L1 dynamics is crucial for improving NSCLC immunotherapy outcomes.
Conclusions:
- Exosomal PD-L1 plays a significant role in NSCLC immune evasion and resistance to current therapies.
- Inhibiting exosome biogenesis offers a promising avenue for novel NSCLC treatment strategies.
- Further research into exosomal PD-L1 is essential for developing next-generation immunotherapies for lung cancer.
